Uncategorized

Gilead takes another big swing at expanding beyond HIV

Gilead takes another big swing at expanding beyond HIV

Published

2 weeks ago

on

Gilead Sciences has dedicated around $11 billion so far this year to three acquisitions meant to bolster its pipelines in cancer and immunology. The pharma company, once criticized for making bad deals, hopes it can …​ ​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version